Oncoteq AG
February 27, 2024
Oncology
Oncoteq is a clinical stage oncology biotech with a focus on first or best-in-class treatments in areas of high unmet need. The company portfolio comprises two highly differentiated assets. TEQ103 has a novel model of action selectively killing ERa+ tumor cells and a potential paradigm shift for patients with hormone receptor positive breast cancers. The second asset, a CD30 directed ADC with an innovative hydrophilic linker is a potential best-in-class treatment for CD30 positive cancers. Both assets are set to enter the clinic in the first half of 2025.